Summary & Overview
HCPCS Level II J1939: Injection, bumetanide 0.5 mg
HCPCS Level II code J1939 designates the injection of bumetanide 0.5 mg, a loop diuretic used in acute fluid management. Nationally, this code is relevant for hospital, emergency department, outpatient infusion, and clinic settings where injectable diuretics are administered for conditions such as edema or acute decompensated heart failure.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise interpretation of what J1939 represents clinically and operationally, an overview of payer coverage considerations, and benchmark elements typically associated with single-dose injectable medications. The publication outlines clinical context for use, common sites of service, and the administrative billing considerations tied to an HCPCS Level II injectable medication code.
This summary provides national-level context, payer scope, and the primary takeaways readers need to understand where and how HCPCS Level II code J1939 is applied in practice. Data not available in the input will be noted where applicable in detailed sections.
Billing Code Overview
HCPCS Level II code J1939 represents Injection, bumetanide, 0.5 mg. This code covers the administration of the loop diuretic bumetanide in a 0.5 milligram dosage form. The service type is medication injection, typically administered as an acute or outpatient therapeutic injection.
The typical site of service for this injection includes hospital inpatient or outpatient settings, emergency departments, infusion centers, and clinic-based procedural areas, depending on clinical need and care setting. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with acute volume overload from congestive heart failure or renal insufficiency presenting to an outpatient infusion center, emergency department, or hospital floor. The clinician orders a single parenteral dose of bumetanide for more rapid diuresis when oral therapy is ineffective or the patient cannot tolerate oral intake. Nursing verifies allergies, current medications, recent potassium and creatinine levels, and monitors vital signs and urine output. The injection J1939 (bumetanide 0.5 mg) is administered via intravenous push or intramuscular injection per facility protocol. Post-administration monitoring includes assessment of blood pressure, electrolytes, renal function, and daily weights; adjustments to ongoing diuretic therapy and electrolyte repletion are documented as indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required to administer or monitor the injection is substantially greater than typical (document medical necessity and increased work). |
23 | Unusual anesthesia |